Long-term outcomes following tumor ablation for treatment of bilateral colorectal liver metastases
- PMID: 23699996
- PMCID: PMC4089883
- DOI: 10.1001/jamasurg.2013.1431
Long-term outcomes following tumor ablation for treatment of bilateral colorectal liver metastases
Abstract
Importance: Ablative therapies extend the capability of delivering potentially curative treatment for bilateral hepatic colorectal metastases.
Objective: To compare the long-term effectiveness of ablation with that of resection in patients with bilateral hepatic colorectal metastases.
Design: Review of a prospective database of 2123 operative cases of hepatic colorectal metastases.
Setting: A large institution with expertise in ablation and resection.
Patients: Patients with bilateral colorectal liver metastases undergoing operation with a curative intent. A total of 141 patients had been treated with bilateral resection (BR) and 95 had undergone ablation.
Interventions: Radiofrequency or microwave ablation alone or in combination with resection (A/R) compared with BR.
Main outcomes and measures: We compared tumor characteristics and operative and postoperative outcomes using χ2 or Wilcoxon tests as appropriate and assessed overall survival differences between the 2 groups using the log-rank test.
Results: During the study, 141 patients were treated with BR and 95 patients with A/R. The A/R group was a significantly poorer prognostic group than the BR group as judged by the Clinical Risk Score (P < .01). There was no difference in median operative time (A/R: 280 minutes, BR: 282 minutes; P = .52), but a lower blood loss (A/R: 300 mL, BR: 500 mL; P < .01) and a shorter length of stay (A/R: 7 days, BR: 9 days; P < .01) was achieved in the A/R group. Long-term outcome was not significantly different between the groups (5-year overall survival, A/R: 56%, BR: 49%; P = .16).
Conclusions and relevance: Treatment of bilateral, multiple hepatic metastases with combined resection and ablation was associated with improved perioperative outcomes without compromising long-term survival compared with bilateral resection. Ablative therapies extend the capability of delivering potentially curative treatment for bilateral hepatic colorectal metastases.
Figures
Comment in
-
To ablate or not to ablate?: that is the question.JAMA Surg. 2013 Jul;148(7):601. doi: 10.1001/jamasurg.2013.1447. JAMA Surg. 2013. PMID: 23700077 No abstract available.
Similar articles
-
[Clinical Application of Microwave Ablation in Potentially Resectable Colorectal Cancer With Simultaneously Multiple Liver Metastases].Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 2024 Apr;46(2):161-168. doi: 10.3881/j.issn.1000-503X.15900. Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 2024. PMID: 38686711 Chinese.
-
Curative-intent treatment of recurrent colorectal liver metastases: A comparison between ablation and resection.Eur J Surg Oncol. 2017 Oct;43(10):1901-1907. doi: 10.1016/j.ejso.2017.08.008. Epub 2017 Aug 26. Eur J Surg Oncol. 2017. PMID: 28888801
-
Microwave ablation with or without resection for colorectal liver metastases.Eur J Surg Oncol. 2013 Aug;39(8):844-9. doi: 10.1016/j.ejso.2013.04.005. Epub 2013 Jun 14. Eur J Surg Oncol. 2013. PMID: 23769976
-
Radiofrequency ablation for colorectal liver metastases.J Visc Surg. 2014 Apr;151 Suppl 1:S33-44. doi: 10.1016/j.jviscsurg.2013.12.005. Epub 2014 Feb 28. J Visc Surg. 2014. PMID: 24582728 Review.
-
Radiofrequency ablation compared to surgical resection for curative treatment of patients with colorectal liver metastases - a meta-analysis.HPB (Oxford). 2017 Sep;19(9):749-756. doi: 10.1016/j.hpb.2017.05.011. Epub 2017 Jul 4. HPB (Oxford). 2017. PMID: 28687147 Review.
Cited by
-
Complex Surgical Strategies to Improve Resectability in Borderline-Resectable Disease.Curr Colorectal Cancer Rep. 2015 Dec;11(6):369-377. doi: 10.1007/s11888-015-0290-5. Epub 2015 Aug 18. Curr Colorectal Cancer Rep. 2015. PMID: 28090195 Free PMC article.
-
Laparoscopic resection combined with ablation for multiple colorectal liver metastases: a multicentre propensity-matched analysis.Surg Endosc. 2025 Aug 13. doi: 10.1007/s00464-025-12040-5. Online ahead of print. Surg Endosc. 2025. PMID: 40801919
-
Colorectal liver metastases: An update on multidisciplinary approach.World J Hepatol. 2019 Feb 27;11(2):150-172. doi: 10.4254/wjh.v11.i2.150. World J Hepatol. 2019. PMID: 30820266 Free PMC article. Review.
-
Locoregional treatment for hepatocellular carcinoma: The best is yet to come.World J Radiol. 2015 Oct 28;7(10):306-18. doi: 10.4329/wjr.v7.i10.306. World J Radiol. 2015. PMID: 26516427 Free PMC article.
-
Eastern Canadian Gastrointestinal Cancer Consensus Conference 2018.Curr Oncol. 2019 Oct;26(5):e665-e681. doi: 10.3747/co.26.5193. Epub 2019 Oct 1. Curr Oncol. 2019. PMID: 31708660 Free PMC article.
References
-
- House MG, Ito H, Gonen M, et al. Survival after hepatic resection for metastatic colorectal cancer: trends in outcomes for 1,600 patients during two decades at a single institution. J Am Coll Surg. 2010;210(5):744–52. 752–5. - PubMed
-
- Nordlinger B, Guiguet M, Vaillant JC, et al. Surgical resection of colorectal carcinoma metastases to the liver. A prognostic scoring system to improve case selection, based on 1568 patients. Association Francaise de Chirurgie. Cancer. 1996;77(7):1254–62. - PubMed
-
- Scheele J, Stang R, Altendorf-Hofmann A, et al. Resection of colorectal liver metastases. World J Surg. 1995;19(1):59–71. - PubMed
-
- Tomlinson JS, Jarnagin WR, DeMatteo RP, et al. Actual 10-year survival after resection of colorectal liver metastases defines cure. J Clin Oncol. 2007;25(29):4575–80. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials